



9th GUILDFORD ADVANCED PAIN & SYMPTOM MANAGEMENT COURSES REFERENCE / READING LIST

METHADONE

Andrew Dickman

- Chalker C et al. Efficacy of low-dose and/or adjuvant methadone in palliative medicine. *BMJ Support Palliat Care* 2019;1–6. Online ahead of print.
- Chou R et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *J Pain*. 2014; 15(4):321-37.
- Courtemanche F et al. Methadone as a Coanalgesic for Palliative Care Cancer Patients. *J Palliat Med*. 2016; 19(9):972-8
- González-Barboteo J et al. Switching Ratio from Parenteral to Oral Methadone 1:1.2 Is Safer Compared with Ratio 1:2 in Patients with Controlled Cancer Pain. *J Palliat Med*. 2021; 24(3):382-390
- Flory JH, Wiesenthal AC, Thaler HT, Koranteng L, Moryl N. Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain. *J Pain Symptom Manage*. 2016; 51(1):79-87.
- Kreuzwiser D et al. Methadone for Pain Management: A Pharmacotherapeutic Review. *CNS Drugs*. 2020; 34(8):827-839.
- Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. *J Pain Palliat Care Pharmacother*. 2005;19(4):13-24
- Makunts T, U A, Atayee RS, Abagyan R. Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids. *Sci Rep*. 2019; 9(1):12490.
- McLean S et al. Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. *J Pain Symptom Manage*. 2015; 50(2):248-259
- McPherson ML et al. Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper. *J Pain Symptom Manage* 2019;57:635-645
- Nicholson AB et al. Methadone for cancer pain. *Cochrane Database Syst Rev*. 2017; 2(2):CD003971
- Treece JM et al. Comprehensive review on methadone induced QT prolongation and torsades. *J Pharmacol Pharmacother* 2018; 9:66-75.

OPIOID-INDUCED CONSTIPATION

Andrew Davies

- Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus

- statement on opioid-induced constipation. *Neurogastroenterology & Motility* 2014; 26: 1386-95.
- Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. *New England Journal of Medicine* 2014; 370: 2387-96.
<https://www.nejm.org/doi/full/10.1056/nejmoa1310246>
 - Davies A, Webber K. Stercoral perforation of the colon: a potentially fatal complication of opioid-induced constipation. *Journal of Pain and Symptom Management* 2015; 50: 260-2.
 - Davies A, Leach C, Caponero R, Dickman A, Fuchs D, Paice J, Emmanuel A. MASCC recommendations on the management of constipation in patients with advanced cancer. *Supportive Care in Cancer* 2020; 28: 23-33.
 - Davies A, Leach C, Butler C, Gregory A, Henshaw S, Minton O, Shorthose K, Batsari KM. Opioid-induced constipation in cancer patients: a “real-world”, multicentre, observational study of diagnostic criteria and clinical features. *Pain* 2021; 162: 309-18.
https://journals.lww.com/pain/Fulltext/2021/01000/Opioid_induced_constipation_in_patients_with.27.aspx
 - Davies AN, Leach C, Butler C, Patel SD, Shorthose K, Batsari K. Opioid-induced constipation: a stepwise treatment algorithm feasibility study. *BMJ Supportive and Palliative Care* 2021. Epub ahead of print.
https://spcare.bmj.com/content/bmjspcare/early/2021/08/03/bmjspcare-2020-002754.full.pdf?casa_token=hFxClXTm6CIAAAAA:hUHY8Zge8SF0pWSmznixdmPJvGJRLzdwCmKdGCKmuvy0YfUtXopvGdWxMpakfb2Y1z2zVnZUXB4KCA
 - Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. *Journal of Clinical Oncology* 2017; 35: 3859-66.
<https://ascopubs.org/doi/10.1200/JCO.2017.73.0853>
 - Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M et al. Bowel Disorders. *Gastroenterology* 2016; 150: 1393-1407.
 - National Institute for Health and Care Excellence. Naloxegol for treating opioid-induced constipation. Technology Appraisal Guidance [TA345]. NICE, London; 2015.
<https://www.nice.org.uk/guidance/ta345>
 - National Institute for Health and Care Excellence. Naldemedine for opioid-induced constipation. Technology Appraisal Guidance [TA651]. NICE, London; 2020.
<https://www.nice.org.uk/guidance/ta651>
 - Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. *Pain Practice* 2017; 17: 820-8.
<https://onlinelibrary.wiley.com/doi/10.1111/papr.12535>
 - Thomas J, Karyer S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE et al. Methylnaltrexone for opioid-induced constipation in advanced illness. *New England Journal of Medicine* 2008; 358: 2332-43.
<https://www.nejm.org/doi/full/10.1056/nejmoa0707377>

RADIOTHERAPY & RADIONUCLIDES FOR BONE METASTASES

May Teoh

- Molecular Biology of Bone Metastasis. Kingsley et al. *Mol Cancer Ther* 2007;6(10):2609-17

- Mechanisms of Bone Metastases. Roodman G. *New Engl J Med* 2004; 350:1655-64
- Biology of bone pain. Goblirsch et al. *Clin Cancer Res* 2006; 12 (20 Suppl)
- EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Handkiewicz-Junak et al. *Eur J Nucl Med and Mol Imaging* 2018; 45:846-859
- EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Poepfel et al. *Eur J Nucl Med and Mol Imaging* 2018; 45:824-845
- Update on the Systematic Review of Palliative Radiotherapy Trials for Bone Metastases. Chow et al. *Clinical Oncology* 2012; 24:112-124
- Overall response rates to radiation therapy for patients with painful uncomplicated bone metastases undergoing initial treatment and retreatment. Bedard et al. *Radiother Oncol* 2014; 112:125-127
- Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compromise from metastatic cancer. The SCORAD Randomised Clinical Trial. Hoskin et al. *JAMA* 2019;322(21):2084-2094
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-term Results of the SABR-COMET Phase II Randomised Trial. Palma et al. *J Clin Oncol* 2020; 38:2830-2838
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. Parker et al. *New Engl J Med* 2013; 369(3):213-223
- A Phase III International Randomised Trial Comparing Single with Multiple Fractions for Re-irradiation of Painful Bone Metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. Chow et al. *Clinical Oncology* 2006;18:125-128
- Re-irradiation for painful bone metastases – a systematic review. Wong et al. *Radiother Oncol* 2014; 110:61-70
- The role of radiation therapy in bone metastases management. De Felice et al. *Oncotarget* 2017;8(15):25691-25699
- Clinical Commissioning Policy Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all aged). NHS England 2020
- Radiotherapy dose fractionation. RCR 2019

WHAT ELSE IS NEW (PAIN)?

Andrew Davies

- Drossman DA, Chang L, Chey WD et al. *Rome IV Functional gastrointestinal disorders: disorders of gut-brain interaction*, 4th ed. Raleigh: The Rome Foundation 2016.
- Drossman DA, Morris CB, Edwards H et al. Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. *Am J Gastroenterol* 2012; 107: 1426-40.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421506/>
- Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. *Nat Rev Gastroenterol Hepatol* 2018; 15: 168-80.
- Davies AN, Leach C. Naloxegol for opioid-induced sphincter of Oddi spasm / dysfunction. *BMJ Support Palliat Care* 2019; 9: 365-6.
- MHRA Drug Safety Update:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/647375/DSU-Sept-pdf.pdf

- Webb NE, Wood DM, Black JC, Amioka E, Dart RC, Dargan PI. Non-medical use of loperamide in the UK and the USA. *QJM* 2020; 113: 25-30.

HISTORICAL ASPECTS OF PAIN

Joanna Bourke

- Biro, David, *The Language of Pain. Finding Words, Compassion, and Relief* (New York: W. W. Norton & Co., 2010).
- Bourke, Joanna and Louise Hide, “Cultures of Harm in Institutions of Care: An Introduction”, *Social History of Medicine*, 31.4 (November 2018), 679-87 <https://academic.oup.com/shm/article/31/4/679/5193072>
- Bourke, Joanna, “Historical Perspectives on Mental Health and Psychiatry”, in Nick Bouras and George Ikkos (eds.), *Mind, State, and Society: Social History of Psychiatry and Mental Health in Britain 1960-2010* (Cambridge: CUP, 2021) https://www.cambridge.org/core/services/aop-cambridge-core/content/view/113978B19265EDAD8CCA7567001475D1/9781911623717AR.pdf/Mind_State_and_Society.pdf?event-type=FTLA.
- Bourke, Joanna, “’Me’ and ‘My Pain’: Neuralgia and a History of the Language of Suffering”, in Deborah Padfield and Joanna M. Zakrzewska (eds.), *Encountering Pain: Hearing, Seeing, Speaking* (London: UCL Press, 2021) <https://www.uclpress.co.uk/products/108203>.
- Bourke, Joanna, “Pain Sensitivity: An Unnatural History from 1800 to 1965”, *Journal of the Medical Humanities* (29 March 2014) <https://eprints.bbk.ac.uk/id/eprint/9551/1/9551.pdf>
- Bourke, Joanna, “Pain, Sympathy, and the Medical Encounter Between the Mid Eighteenth and Mid Twentieth Centuries”, *Historical Research*, 85.229 (August 2012), 430-68 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906540/>.
- Bourke, Joanna, “Police Surgeons and Victims of Rape: Cultures of Harm and Care”, *Social History of Medicine*, 31.4 (November 2018), 679-87
- Bourke, Joanna, “Prothero Lecture: What is Pain? A History”, *Transactions of the Royal Historical Society*, 23 (December 2013), 155-73, free full text at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874838/>.
- Bourke, Joanna, *The Story of Pain: From Prayer to Painkillers* (Oxford: Oxford University Press, 2014).
- Bourke, Joanna, *What It Means To Be Human, Historical Reflections 1791 to the Present* (London: Virago, 2011).
- Coakley, Sarah and Kay Kaufman Shelemay (eds.), *Pain and its Transformations. The Interface of Biology and Culture* (Cambridge, Mass.: Harvard University Press, 2007).
- Daudet, Alphonse, *In the Land of Pain*, translated and edited by Julian Barnes (London: Jonathan Cape, 2002).
- Hide, Louise, Joanna Bourke, and Carmen Mangion, “Perspectives on Pain”, *19. Interdisciplinary Studies in the Long Nineteenth Century* 15 (2012). <https://19.bbk.ac.uk/article/id/1605/>
- Woolf, Virginia, *On Being Ill*, intro. by Hermione Lee, 1st pub. 1930 (Ashfield, Massachusetts: Paris Press, 2002).

“OFF-LICENCE PRESCRIBING

Jo Thompson

- Anonymous. The licensing of medications in the UK. *Drugs and therapeutics bulletin*. 2009; 47(4): 45-48
- Aronson J, Ferner R. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. *British Journal of Clinical Pharmacology*. 2017; 83: 2615-2625
- Culshaw J, Kendal D, et al. Off-label prescribing in palliative care: A survey of independent prescribers. *Palliative Medicine*. 2012; 27(4): 314-319
- Davies AN, Leach C. Naloxegol for opioid induced sphincter of oddi spasm / dysfunction. *BMJ Supportive & Palliative Care*. 2019; 9:365-366
- Diaz J. A decision analysis model to justify and approve off-label drug use in pain and palliative care. *World Institute of Pain* 2008; 8(3): 153-154
- Eguale T, Buckeridge D, et al. Association of off-label drug use and adverse events in an adult population. *JAMA Internal Medicine*. 2016; 176(1): 55-63
- Good C, Gellad W. Off-label drug use and adverse events. Turning up the heat on off-label prescribing. *JAMA Internal Medicine*. 2016; 176(1): 63-64
- Hageman V, Bausewein C, et al. Drug use beyond the licence in palliative care: A systematic review and narrative synthesis. *Palliative Medicine*. 2019; 33(6): 650-662
- <https://www.nice.org.uk/about/nice-communities/nice-and-the-public/making-decisions-about-your-care/information-for-the-public-on-medicines> (accessed 24th July 2021)
- <https://www.gov.uk/drug-safety-update/off-label-or-unlicensed-use-of-medicines-prescribers-responsibilities> (accessed 24th July 2021)
- <https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices> (accessed 24th July 2021)
- <https://www.rpharms.com/resources/frameworks/prescribers-competency-framework> (accessed 24th July 2021)
- Keller D. In defense of off-label prescribing. *JAMA Internal Medicine*. 2016; 176(6): 861
- Kwon J, Kim M, et al. Off-label medication use in the inpatient palliative care unit. *Journal of Pain and Symptom Management*. 2017; 54(1): 46-54
- Liperoti R, Fusco D, et al. Balancing the risks and benefits of antipsychotic medications for symptom management in older patients with cancer. *Journal of Geriatric Oncology*. 2018; 9: 693-695
- Morales D, Guthrie B. Off-label prescribing of antidepressants. *BMJ*. 2017; 356: 1-2
- Phillips J. The challenge of off-label prescribing. *International journal of palliative nursing*. 2015; 21(9): 419
- Remi C, Weingartner K, et al. Off-label drugs in palliative care: a group delphi treatment recommendation process. *BMJ Supportive & Palliative care*. 2020; 0:1-8
- Ruan X, Kaye A. Off-label prescribing: justified or not? *American Journal of Medical Quality*. 2016; 31(2): 101-102
- Saiyed M, Ong P, et al. Off-label drug use in oncology: a systematic review of the literature. *Journal of Clinical Pharmacology and Therapeutics*. 2017; 42: 251-258
- To T, Agar M et al. Off-label prescribing in palliative care – a cross sectional national survey of palliative medicine doctors. *Palliative Medicine*. 2012; 27(4): 320-328
- Todd J, Davies A. Use of off-licensed medications in palliative medicine. *Palliative Medicine (correspondence)* 1999; 13: 466

- Toscani F. Prescribing in palliative care: A quest for appropriateness. *Palliative Medicine*. 2013; 27(4): 293-294
- Toscani F, Di Giulio P, et al. Off-label prescriptions in Italian hospices: A National survey. *Journal of Pain and Symptom Management*. 2009; 38(3): 365-371
- Twycross A, Wilcock A (eds) *Palliative Care Formulary*. 2017. Sixth edn. Palliatiivedrugs.com
- Verhagen C, Niezink A, et al. Off label use of drugs in pain medicine and palliative care: An algorithm for the assessment of its safe and legal prescription. *Pain Practice*. 2008; 8(3): 157-163
- Vrancken I. Off-label prescription of medication. *European Journal of Health Law*. 2015; 22: 165-186
- Wallach J, Ross J. Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. *JAMA*. 2018; 319(8):776-778
- Wittich C, Burkle C, et al. Ten common questions (and their answers about off-label drug use). *Mayo Clinic Proceedings*. 2017; 87(10): 982-990

QTC PROLONGATION AND EXTRAPYRAMIDAL ADVERSE EFFECTS

Paul Paes

- Bor, Serhat et al. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. *United European gastroenterology journal* 2018; 6(9): 1331-1346
- Bruera ED, MacEachern TJ, Spachynski KA et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. *Cancer* 1994; 74(12): 3204–3211
- Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. *J Pain Symptom Manag* 2000; 19(6): 427–435
- Bruera E, Moyano JR, Sala R et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. *J Pain Symptom Manage* 2004; 28(4):381–388
- Burbuque, I., Boettger, S., Schubert, M., Bettex, D., & Rudiger, A. QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery: A cohort study and review of the literature. *Palliative and Supportive Care* 2020; 18(4): 447-459
- Corli O, Cozzolino A, Battaiotto L. Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. *J Pain Symptom Manag* 1995; 10(7): 521–526
- Cox L, Darvill E, Dorman S. Levomepromazine for nausea and vomiting in palliative care. *Cochrane Database Syst Rev*. 2015(11):CD009420
- www.Crediblemeds.org
- Digges M, Hussein A, Wilcock A, Crawford GB, Boland JW, Agar MR, Sinnarajah A, Currow DC, Johnson MJ. Pharmacovigilance in Hospice/Palliative Care: Net Effect of Haloperidol for Nausea or Vomiting. *J Palliat Med*. 2018;21(1):37-43
- Drew, B et al. “Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.” *Circulation* 2010; 121(8): 1047-60
- Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. *Arch Intern Med*. 1993; 153(12): 1469-75

- Hardy JR, Bundock D, Cross J, Gibbons K, Pinkerton R, Kindl K, Good P, Philip J. Prevalence of QTc Prolongation in Patients With Advanced Cancer Receiving Palliative Care-A Cause for Concern? *J Pain Symptom Manage* 2020;59(4): 856-863
- Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. *J Clin Psychopharmacol*. 2006;26(2):192-7
- Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. *Am J Psychiatry*. 2004;161(1):160-3
- Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. *J Clin Psychiatry*. 2004;65 Suppl 9:21-4
- Kaye, A. et al. QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes. *Journal of Anesthesia* 2013; 27: 575-587
- Kondo T, Otani K, Tokinaga N, Ishida M, Yasui N, Kaneko S. Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist. *J Clin Psychopharmacol*. 1999;19(1):45-50
- Murray-Brown F, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. *Cochrane Database Syst Rev*. 2015(11):CD006271
- Mystakidou K, Befon S, Trifyllis J, Lioffi C, Papadimitriou J Tropisetron versus metoclopramide in the control of emesis in far-advanced cancer. *Oncologist* 1997; 2(5):319–323
- Mystakidou K, Befon S, Lioffi C, Vlachos L Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. *Cancer* 1998; 83(6):1214–1223
- Parlak I, Atilla R, Cicek M, Parlak M, Erdur B, Guryay M, Sever M, Karaduman S. Rate of metoclopramide infusion affects the severity and incidence of akathisia. *Emerg Med J*. 2005;22(9):621-4
- Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. *Schizophrenia Bulletin*. 2012; 38(1):167-177
- Sabine et al. Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults. *Journal of the American College of Cardiology* 2006; 47(2): 362-367
- Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges. *Curr Neuropharmacol*. 2017;15(5):789-798
- Saudemont G, Prod'Homme C, Da Silva A, Villet S, Reich M, Penel N, Gamblin V. The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. *BMC Palliat Care*. 2020;19(1):56
- Sykes DA, Moore H, Stott L, et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. *Nat Commun*. 2017;8(1):763
- Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. *Cochrane Database Syst Rev*. 2018;9(9):CD012555
- Vandael, E., Vandenberk, B., Vandenbergh, J. et al. Risk factors for QTc-prolongation: systematic review of the evidence. *Int J Clin Pharm* 2017; 39: 16–25
- Walker G, Wilcock A, Carey AM, Manderson C, Weller R, Crosby V. Prolongation of the QT interval in palliative care patients. *J Pain Symptom Manage*. 2003; 26(3): 855-9
- Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer. *Support Care Cancer*. 2017; 25(1):333-340

- Wong A, Keith C, Gregory H & Liew D Palliative and Supportive Care Prescribing Considerations Around QT Prolongation Risk in the Context of COVID-19 (Coronavirus Disease 2019) Management. *Journal of Pain & Palliative Care Pharmacotherapy* 2020; 34(4): 237-239

WHAT ELSE IS NEW (SYMPTOMS)?

Andrew Davies

- Davies A, Cleary NM. Letter to the Editor in response to "What is the impact of clinically assisted hydration in the last days of life? A systematic literature review and narrative synthesis". *BMJ Support Palliat Care* 2021 (on-line).
<https://spcare.bmj.com/content/11/1/68.responses>
- Davies AN, Waghorn M, Webber K, Johnsen S, Mendis J, Boyle J. A cluster randomised feasibility trial of clinically assisted hydration in cancer patients in the last days of life. *Palliative Medicine* 2018; 32: 733-43.
- Good P, Richard R, Syrmiss W et al. Medically assisted hydration for adult palliative care patients. *Cochrane Database of Systematic Reviews* 2014, Issue 4. Art. No.: CD006273.
<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006273.pub3/full>
- Kingdon A, Spathis A, Brodrick R, Clarke G, Kuhn I, Barclay S. What is the impact of clinically assisted hydration in the last days of life? A systematic literature review and narrative synthesis. *BMJ Support Palliat Care* 2021; 11: 68-74.
<https://spcare.bmj.com/content/11/1/68.long>
- National Institute for Health and Care Excellence. *Intravenous fluid therapy in adults in hospital*, 2013.
<http://guidance.nice.org.uk/CG174>